Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Allocetra-OTS |
Synonyms | |
Therapy Description |
Allocetra-OTS is a cellular therapy comprising mononuclear cells induced to undergo early apoptosis, which potentially decreases tumor growth (Journal for ImmunoTherapy of Cancer 2022;10). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Allocetra-OTS | Allogeneic ex-vivo-treated PBMCs|Allocetra | Allocetra-OTS is a cellular therapy comprising mononuclear cells induced to undergo early apoptosis, which potentially decreases tumor growth (Journal for ImmunoTherapy of Cancer 2022;10). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05581719 | Phase Ib/II | Allocetra-OTS Allocetra-OTS + Tislelizumab Allocetra-OTS + Nivolumab | A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy | Terminated | ISR | ESP | 0 |